CN113613642B - 取代的氨基-硫醇和氨基-二硫化物化合物及其用途 - Google Patents

取代的氨基-硫醇和氨基-二硫化物化合物及其用途 Download PDF

Info

Publication number
CN113613642B
CN113613642B CN202080024298.3A CN202080024298A CN113613642B CN 113613642 B CN113613642 B CN 113613642B CN 202080024298 A CN202080024298 A CN 202080024298A CN 113613642 B CN113613642 B CN 113613642B
Authority
CN
China
Prior art keywords
compound
cystamine
cysteamine
deuterated
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080024298.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113613642A (zh
Inventor
兰詹·多希尔
C·巴拉托雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN113613642A publication Critical patent/CN113613642A/zh
Application granted granted Critical
Publication of CN113613642B publication Critical patent/CN113613642B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080024298.3A 2019-03-26 2020-03-26 取代的氨基-硫醇和氨基-二硫化物化合物及其用途 Active CN113613642B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823892P 2019-03-26 2019-03-26
US62/823892 2019-03-26
PCT/US2020/025067 WO2020198529A1 (en) 2019-03-26 2020-03-26 Substituted amino-thiol and amino-disulfide compounds, and uses thereof

Publications (2)

Publication Number Publication Date
CN113613642A CN113613642A (zh) 2021-11-05
CN113613642B true CN113613642B (zh) 2024-08-06

Family

ID=72610131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024298.3A Active CN113613642B (zh) 2019-03-26 2020-03-26 取代的氨基-硫醇和氨基-二硫化物化合物及其用途

Country Status (5)

Country Link
US (1) US12391643B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946298A4 (cg-RX-API-DMAC7.html)
JP (1) JP7538541B2 (cg-RX-API-DMAC7.html)
CN (1) CN113613642B (cg-RX-API-DMAC7.html)
WO (1) WO2020198529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
JP2022188184A (ja) * 2022-10-04 2022-12-20 Sc有機化学株式会社 硫黄化合物含有組成物及び樹脂組成物
CN115745857B (zh) * 2022-10-28 2025-10-17 中国医学科学院放射医学研究所 一类口服给药的活性氧响应的硫酯类化合物、合成方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442704A (zh) * 2011-02-23 2013-12-11 拉瓦勒大学 用于治疗帕金森病的胱胺类似物
CN107106875A (zh) * 2014-11-05 2017-08-29 霍里森罕见药有限公司 使用半胱胺组合物治疗亨廷顿氏病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254730A (en) * 1992-01-14 1993-10-19 Kilgore James L Production of amino acids and amino acid derivatives bearing isotopic hydrogen labels
WO2007089670A2 (en) 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2009070781A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US8530479B2 (en) 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
MX392606B (es) * 2016-03-17 2025-03-24 Thiogenesis Therapeutics Inc Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
WO2021022012A1 (en) 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442704A (zh) * 2011-02-23 2013-12-11 拉瓦勒大学 用于治疗帕金森病的胱胺类似物
CN107106875A (zh) * 2014-11-05 2017-08-29 霍里森罕见药有限公司 使用半胱胺组合物治疗亨廷顿氏病的方法

Also Published As

Publication number Publication date
EP3946298A4 (en) 2023-01-25
EP3946298A1 (en) 2022-02-09
US12391643B2 (en) 2025-08-19
JP2022525148A (ja) 2022-05-11
CN113613642A (zh) 2021-11-05
JP7538541B2 (ja) 2024-08-22
WO2020198529A1 (en) 2020-10-01
US20220135524A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
JP6177832B2 (ja) アルギナーゼ阻害剤および使用方法
US9993449B2 (en) (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma
CN115490681B (zh) 三嗪衍生物
TW200843778A (en) Pterin analogs
JP7538541B2 (ja) 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用
EP3316877B1 (en) Ado-resistant cysteamine analogs and uses thereof
US20190040029A1 (en) A type of aryl benzofuran amidated derivative and medical use thereof
US12221428B2 (en) Use of deuterated empathogens as therapeutic agents
WO1999057120A9 (en) Novel serotonin-like 9-substituted hypoxanthine and methods of use
EP1143951A2 (en) Antimalarial agents
JP2004517105A (ja) ビグアニンとキャリア、例えばメトホルミンとアルギニンの薬効的関連
CA3053344A1 (en) Treatment of diabetes and associated metabolic conditions with epigenetic modulators
CN109096219B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
ES2963560T3 (es) Compuesto piramidin-5-carboxamida
US11203596B2 (en) Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
US20250066292A1 (en) Cysteamine and/or cystamine prodrugs
SG188472A1 (en) Prodrugs of guanfacine
KR20160146689A (ko) 파킨슨병을 치료하기 위한 도파민 효능제 및 l-dopa 유도체를 포함하는 조성물
CN111163765A (zh) 用于抑制胆碱向三甲胺(tma)的转化的方法
CN110577480A (zh) 一种抗β淀粉样蛋白活性的化合物的制备方法和应用
US9505743B2 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
JP3969831B2 (ja) ハイドロキシプロリン誘導体
US20240245647A1 (en) Isomerohydrolase inhibitor for treatment of atrophic form of age-related macular degeneration and stargardt disease
US20260008750A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
JP2011190257A (ja) 組織線維化疾患の予防または治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant